Long-term follow-up of people previously treated with KYV-101 for autoimmune diseases
Follows adults treated with KYV-101 earlier to watch for delayed side effects.
Plain-language title generated from the registry record
Registry title: A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Key facts
- Where
- Berlin, Bochum, Hamburg, and Hanover, GermanySee the 4 sites
- Phase
- Phase 2/3
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- Katholisches Klinikum Bochum gGmbHBochum, GermanyTaking people
- Leibniz Institute Of VirologyHamburg, GermanyTaking people
- Medizinische Hochschule HannoverHanover, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kyverna Therapeutics
- Trial code
- NCT07403188EU 2024-511198-31-00
- Record updated
- 11 February 2026
- Original description
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).Read full original descriptionShow less
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).
This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Inclusion: Provided informed consent for the LTFU study; Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol.
Exclusion: Not applicable.